Cargando…
Angiostatic Peptide, Endostatin, Predicts Severity in Pediatric Congenital Heart Disease–Associated Pulmonary Hypertension
BACKGROUND: Endostatin, an angiogenic inhibitor, is associated with worse pulmonary arterial hypertension (PAH) outcomes in adults and poor lung growth in children. This study sought to assess whether endostatin is associated with disease severity and outcomes in pediatric PAH. METHODS AND RESULTS:...
Autores principales: | Daly, Caroline M., Griffiths, Megan, Simpson, Catherine E., Yang, Jun, Damico, Rachel L., Vaidya, R. Dhananjay, Williams, Monica, Brandal, Stephanie, Jone, Pei‐Ni, Polsen, Cassandra, Ivy, D. Dunbar, Austin, Eric D., Nichols, William C., Pauciulo, Michael W., Lutz, Katie, Nies, Melanie K., Rosenzweig, Erika B., Hirsch, Russel, Yung, Delphine, Everett, Allen D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8751905/ https://www.ncbi.nlm.nih.gov/pubmed/34622662 http://dx.doi.org/10.1161/JAHA.120.021409 |
Ejemplares similares
-
The angiostatic peptide endostatin enhances mortality risk prediction in pulmonary arterial hypertension
por: Simpson, Catherine E., et al.
Publicado: (2021) -
COL18A1 genotypic associations with endostatin levels and clinical features in pulmonary arterial hypertension: a quantitative trait association study
por: Simpson, Catherine E., et al.
Publicado: (2022) -
Pediatric Pulmonary Hypertension: Insulin Like Growth Factor Binding Protein 2 is a novel marker associated with disease severity and survival
por: Griffiths, Megan, et al.
Publicado: (2020) -
Hepatoma‐derived growth factor is associated with pulmonary vascular remodeling and PAH disease severity and survival
por: Yang, Jun, et al.
Publicado: (2022) -
Insulin‐like growth factor binding Protein‐4: A novel indicator of pulmonary arterial hypertension severity and survival
por: Torres, Guillermo, et al.
Publicado: (2023)